COMMON STOCK PURCHASE WARRANT CURATIVE BIOTECHNOLOGY, INC.Curative Biotechnology Inc • September 9th, 2022 • Biological products, (no disgnostic substances)
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Puritan Partners LLC, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the five (5) year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Curative Biotechnology, Inc., a Florida corporation (the “Company”), up to 22,857,143 shares of common stock, of the Company (the “Common Stock”) (subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITY AGREEMENTSecurity Agreement • September 9th, 2022 • Curative Biotechnology Inc • Biological products, (no disgnostic substances) • New York
SECURITY AGREEMENT, dated as of March 2, 2022 (this “Agreement”), between Curative Biotechnology, Inc., a Florida limited liability company (the “Company” or the “Debtor” and collectively with any other Debtor from time to time hereunder, the “Debtors”) and the holders of the Company’s 12.5% Senior Secured Note due March 2, 2023 in aggregate principal amount of $1,142,857.14 (the “Note”), signatory hereto, its endorsees, transferees and assigns (individually referred to as, the “Secured Party” and collectively referred to as, the “Secured Party”). Any terms not defined herein shall have the definition ascribed to them in the Purchase Agreement and Note.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 9th, 2022 • Curative Biotechnology Inc • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as March 2, 2022, among Curative Biotechnology, Inc, a Florida corporation whose principal place of business is located at 1825 NW Corporate Blvd., Suite 110 Boca Raton, FL 33431 (the “Company”) and the Purchaser identified on the signature pages hereto (including their successors and assigns, the “Purchaser”).
NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE...Curative Biotechnology Inc • September 9th, 2022 • Biological products, (no disgnostic substances) • New York
THIS 12.5% ORIGINAL ISSUE DISCOUNT SENIOR SECURED NOTE is one of a series of duly authorized and validly issued 12.5% Original Issue Discount Senior Secured Notes of Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Corporate Blvd., Suite 110 Boca Raton, FL 33431, designated as its 12.5% Original Issue Discount Senior Secured Note due March 2, 2023 (this Note, the “ Note “ and, collectively with the other Notes of such series, the “ Notes”). The Notes shall be convertible into shares of common stock of in the Company in accordance with the terms of the Notes.
LOCK-UP AGREEMENTLock-Up Agreement • September 9th, 2022 • Curative Biotechnology Inc • Biological products, (no disgnostic substances) • New York
Re: Securities Purchase Agreement, dated as of March 2, 2022 (the “Purchase Agreement”), between Curative Biotechnology, Inc., a Florida corporation (the “Company”), and the purchaser signatory thereto (the “Purchaser”)
First Amendment to Transaction DocumentsTransaction Documents • September 9th, 2022 • Curative Biotechnology Inc • Biological products, (no disgnostic substances)
This First Amendment to the Transaction (this “Amendment”) is entered into as of August 18, 2022, by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Corporate Blvd., Suite 110 Boca Raton, FL 33431, each a “Party” and collectively the “Parties”. Capitalized terms used herein without definition shall have the meanings ascribed to them in the Securities Purchase Agreement, dated as of March 2, 2022, entered into between the Parties (the “Securities Purchase Agreement”)
FIRST AMENDMENT TO LICENSE, FUNDING AND OPERATIONAL AGREEMENTLicense, Funding and Operational Agreement • September 9th, 2022 • Curative Biotechnology Inc • Biological products, (no disgnostic substances)
THIS FIRST AMENDMENT (the “Amendment”) to the License, Funding and Operational Agreement between Mid-Atlantic BioTherapeutics, Inc. (“Licensor”) and Curative Biotechnology, Inc. (“Licensee”) executed October 1, 2021 for a COVID-19 Vaccine (the “Agreement”), is made by Licensor and Licensee,
SETTLEMENT AGREEMENT AND RELEASESettlement Agreement and Release • September 9th, 2022 • Curative Biotechnology Inc • Biological products, (no disgnostic substances) • Florida
THIS SETTLEMENT AGREEMENT AND RELEASE (the “Settlement Agreement”), is made and entered into as of this 9th day of August 2021 by and between: (i) FORTIFIED MANAGEMENT GROUP, LLC (“Fortified”) and JODY R. SAMUELS (“Samuels”) on the one hand; and CURATIVE BIOTECHNOLOGY, INC. f/k/a CONNECTYX TECHNOLOGIES HOLDINGS GROUP, INC., on the other hand (“Curative” and together with Fortified and Samuels, the “Parties”).
SPECIAL ADVISOR TO THE BOARD OF DIRECTORS AND THE CEO AGREEMENTBoard of Directors and the Ceo Agreement • September 9th, 2022 • Curative Biotechnology Inc • Biological products, (no disgnostic substances) • Delaware
THIS AGREEMENT is made and entered into effective as of SEPTEMBER 27, 2021, (the “Effective Date”), by and between Curative Biotechnology Inc., a Florida corporation (the “Company”) with its principal place of business located at 1825 NW Corporate Blvd #110 Boca Raton, Florida , and Sohn Health Strategies LLC, a New Jersey limited liability company (“Advisor”) with a principal place of business at 5 Hidden Acres Drive, Voorhees, NJ 08043.
FIRST AMENDMENT TO LICENSE, FUNDING AND OPERATIONAL AGREEMENTLicense, Funding and Operational Agreement • September 9th, 2022 • Curative Biotechnology Inc • Biological products, (no disgnostic substances)
THIS IS THE FIRST AMENDMENT (the “Amendment”) to the License, Funding and Operational Agreement for rabies immunotherapy (the “Agreement”) between Mid-Atlantic BioTherapeutics, Inc. (“Licensor”) and Curative Biotechnology, Inc., formerly Connectyx, (“Licensee”) originally executed September 30th, 2020.
